Caissa Capital Management ltd.'s Form 4 filing
Avalo Therapeutics, Inc. (AVTX) · filed May 16, 2023
- Accession no.
- 0001929354-23-000008
- Filed
- May 16, 2023
- Trade date
- May 12-16, 2023
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 3 non-derivative transactions. Open-market purchases total $11.0K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Caissa Capital Management ltd.CIK 0001929354 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| May 12, 2023 | Common stock | PPurchaseAcquired | +2,285 | $2.45 | +$5,598.25 | 1,344,985 | Indirect | |
| May 15, 2023 | Common stock | PPurchaseAcquired | +1,715 | $2.55F2 | +$4,373.25 | 1,346,700 | Indirect | |
| May 16, 2023 | Common stock | PPurchaseAcquired | +379 | $2.75 | +$1,042.25 | 1,347,079 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $2.45 to $2.79, inclusive.
Referenced by the price of 1 transaction in Table I.